1242329-41-4

Upstream product

• 299176-17-3 N-(2-nitro-5-chlorophenyl)-N-methylcarbamic acid t-butyl ester 
• 41288-96-4 6-chloropyridine-3-ol 

Downstream Products

• 1242329-45-8 3-({6-[(6-chloropyridin-3-yl)oxy]-1-methyl-1H-benzimidaol-2-yl}methoxy)benzoic acid 
• 1242328-90-0 3-({6-[(6-methoxypyridin-3-yl)oxy]-1-methyl-1H-benzimidazol-2-yl}methoxy)benzoic acid 
• 1242329-44-7 methyl 3-({6-[(6-chloropyridin-3-yl)oxy]-1-methyl-1H-benzimidaol-2-yl}methoxy)benzoate 
• 1242329-43-6 methyl 3-(2-{2-[(tert-butoxycarbonyl)(methyl)amino]-4-[(6-chloropyridin-3-yl)oxy]anilino}-2-oxoethoxy)benzoate 
• 1242329-42-5 tert-butyl {2-amino-5-[(6-chloropyridin-3-yl)oxy]phenyl}methylcarbamate 

Relevant academic research and scientific papers

Structure-Activity Relationship Studies of 3- or 4-Pyridine Derivatives of DS-6930

Derivatization efforts were continued to discover backups for a potent selective PPARγ modulator, DS-6930. In this Letter, the replacement of 2-pyridine ring in DS-6930 with 3- or 4-pyridyl group is reported. As the introduction of substituents on the pyridine ring did not provide potent partial agonists, modifications of benzimidazole ring were explored to discover potent intermediate agonists. 4′-Alkoxy substituted benzimidazoles failed to show potent efficacy in vivo, whereas 7′-fluoro benzimidazole 3g (DS19161384) was found to result in robust plasma glucose reductions with excellent DMPK profiles.

PYRIDINE DERIVATIVE

The present invention relates to a novel pyridine derivative or a pharmacologically acceptable ester thereof, or a pharmacologically acceptable salt of the derivative or ester, which has an excellent hypoglycemic effect or treats and/or prevents the onset